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Abstract: For a number of years, high-density lipoprotein (HDL) has been recognized to have an athero-protective role 
by promoting reverse lipid transport, a process facilitating the cholesterol efflux from atherosclerotic plaques in the ar-
tery wall and its elimination by the liver via biliary excretion. 
  On the contrary, low-density lipoprotein (LDL) particles carry cholesterol to the organs and tissues where it can be 
used to produce hormones or maintain cell metabolism. When an imbalance develops, as a result of either an excess 
level of cholesterol associated with LDL (LDL-C) or a less effective cholesterol elimination by HDL (HDL-C), this 
causes an excess of cholesterol to be transported to the tissues and promotes the deposition of cholesterol. This often 
occurs in the artery walls, particularly in the coronary arteries. There is no approved medical treatment for directly sup-
pressing or treating the atherosclerotic plaque once it is formed. Epidemiological studies have shown that the risk of 
developing cardio-vascular disease (CVD) is higher in patients with low levels of HDL-C regardless of LDL-C levels, 
even in patients optimally treated with LDL-C-lowering therapies. These data highlight that low HDL-C and low HDL 
particle number is an important target of therapies aiming to reduce the residual risk of CVD. 
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he main cholesterol transporters in the blood 
are lipoproteins, especially low-density lipo-
protein (LDL) and high-density lipoprotein 
(HDL) particles. LDL particles carry cholesterol to the 
organs and tissues where it can be used to produce 
hormones, maintain cell metabolism or be metabo-
lized into, for example, biliary acids. HDL particles 
take excess cholesterol from the tissues by a pathway 
called reverse lipid transport (RLT), and carry it to the 
liver for either storage, recycling or elimination[1] 
(Figure 1). An HDL is a complex containing apolipo-
protein (apo) A-I and phospholipids bound together to 
form a nanoparticle synthesized in the liver or the bo-
wel. The newly synthesized complex (called a pre-β 
HDL particle[2]) comprises a negatively charged nas-
cent disc-shaped particle of several nanometers in  
diameter. In the circulation, the empty nascent pre-β 
HDL particle captures cholesterol and other lipids and 
transforms into a spherical particle, known as mature 
HDL (Figure 2). 
In young healthy individuals, the production and 
elimination of cholesterol are in equilibrium. However, 
with increasing age and rich diet, an imbalance often 
develops, as a result of either an excess level of cho-
lesterol associated with LDL (LDL-C) or a less effec-
tive cholesterol elimination by HDL (HDL-C). This 
imbalance causes an excess of cholesterol to be trans-
ported to the tissues and promotes the deposition of 
cholesterol. This may occur throughout the tissues of 
the body, but often occurs in the artery walls, particu-
larly in the arteries that supply the heart muscle[3]. The 
resulting cholesterol deposits can cause potentially 
life-threatening complications, such as vascular 
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Figure 2 HDL maturation pathway. 
 
inflammation and the formation of atherosclerotic pla-
ques, which may stenose or narrow the arteries caus-
ing chest pain on exertion or even at rest. The unex-
pected rupture of a plaque can result in sudden ob-
struction of these arteries, leading to acute coronary 
syndrome (ACS), unstable angina pectoris or a myo-
cardial infarction (MI), and could be fatal. Despite 
secondary prevention measures, including drugs such 
as aspirin and other antiplatelet agents, beta-blockers, 
angiotensin converting enzyme (ACE) inhibitors and 
statins, the cardiovascular event recurrence rate in 
post-ACS patients remains high, particularly within 
the first few weeks post the initial ACS event. This 
highlights the significant unmet medical need in this 
patient group.   
The process of cholesterol accumulation takes place 
over many years, even decades, and individuals may 
remain asymptomatic for long periods of time despite 
developing significant risk of cardiovascular disease 
(CVD). The imbalance in cholesterol regulation may 
be exacerbated by other CVD risk factors including 
gender, hypertension, smoking, diabetes, obesity, ge-
netic predisposition, physical inactivity and a high-fat 
diet[4]. Consequently, a healthy low-fat diet, especially 
low in saturated fats, not smoking, physical activity 
and reduced stress are among public health recom-
mendations to lower the risk of CVD[5]. 
There is no approved medical treatment for directly 
suppressing or treating the atherosclerotic plaque once 
it is formed. Mechanical removal of the atherosclerot-
ic plaques (rotatory atherectomy) or restoring the ar-
tery diameter by using a stent may be performed. 
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However, these invasive methods only treat the dis-
ease locally, while other vessels may also be loaded 
with plaque. These local procedures cannot treat a 
disease such as atherosclerosis, which is systemic and 
marked by accumulation of cholesterol in all vessel 
walls, with multiple plaques in several vascular beds. 
Atherosclerotic disease is treated indirectly by reduc-
ing cholesterol levels in the blood. Current medical 
recommendations for the treatment of excessive cho-
lesterol include pharmacotherapy with LDL-C-lower-
ing agents such as statins, inhibitors of PCSK9 pre-
venting LDL receptor elimination (proteolysis), bile- 
acid sequestering resins and intestinal cholesterol ab-
sorption inhibitors. These aim to reduce LDL-C levels 
in the circulation, with the long-term goal of limiting 
or preventing continued accumulation of cholesterol in 
the vessel walls. These preventative strategies have 
proven efficacy for reducing CVD events by one third, 
and have become the standard of care recommended 
by health authorities for the treatment of CVD risk. 
An important limitation of LDL-C-lowering thera-
pies is that, in most patients, treatment is initiated 
around age of 30 to 40 years, when cholesterol has alr-
eady been accumulating in their vessel walls for dec-
ades. In addition, these treatments have only a modest 
effect on regression of the atherosclerotic plaque[6] 
which is only achieved when very low levels of LDL-C 
(< 70 mg/dL) are attained with high doses of the most 
potent statins administered for several years. Such low 
LDL-C levels are often not attainable either because 
of the increased risk of side effects at higher doses or 
because of poor compliance with long-term treat-
ment[7]. The recent results of the clinical trial IM-
PROVE-IT, conducted in patients who had experienced 
an ACS, demonstrated the difficulty in achieving fur-
ther CVD risk reduction with intensive LDL-C lo-
wering. In this study, long-term combination therapy 
(ezetimibe plus simvastatin for 7 years) to achieve an 
additional LDL-C reduction of 15–20% compared with 
simvastatin alone, resulted in only a small reduction 
(2%) in absolute risk of the primary endpoint of CVD 
death, nonfatal MI, unstable angina, coronary revascul-
arization or stroke (32.7% and 34.7%, respectively)[8].  
The findings of IMPROVE-IT[9,10], and those of 
other LDL-C-lowering studies, have highlighted that 
despite the one-third reduction in risk with LDL-C 
lowering, CVD risk remains high in patients whose 
LDL-C levels are below target level. Consequently, 
many patients who have a CVD event present with 
relatively “normal” LDL-C levels. There is a still a 
significant unmet medical need for addressing the re-
maining two-thirds of CVD risk[11]. This presents an 
opportunity for new therapies, which may directly 
eliminate atherosclerotic plaque, to reduce the risk of 
CVD. Recently, PCSK9 inhibitors, monoclonal anti-
bodies directed against PCSK9 enzyme, were ap-
proved to treat high risk patients with CVD. They are 
very effective in lowering LDL-C on top of standard 
of care, and safety and effect on CV outcome are cur-
rently being evaluated in long term studies. It is how-
ever unlikely that the CVD risk will be completely 
abolished as the cause for atherosclerotic plaque is 
multifactorial and LDL lowering has limited effect on 
already present plaques. 
One factor that contributes to the residual risk of 
CVD is cholesterol imbalance resulting from a defect 
in cholesterol elimination by HDL particles rather than 
by an “excess” of cholesterol transported by LDL par-
ticles. The protective role of HDL particles has been 
demonstrated in several epidemiological studies 
(FRAMINGHAM, MONICA, and PROCAM). These 
studies have shown that the risk of developing CVD is 
higher in patients with low levels of HDL-C regard-
less of LDL-C levels, even in patients optimally treated 
with LDL-C-lowering therapies (Figure 3)[12,13]. Other 
large-scale studies have demonstrated that the level of 
apoA-I (the main protein in HDL particles) represents 
a better predictive factor of CVD events. Recently, 
the number of HDL particles rather than the amount 
of HDL-C was demonstrated to be more relevant to 
protect against CVD (MESA trial[14]) including in 
patients treated with statins (JUPITER trial[6]). These 
studies are part of a large body of clinical evidence 
demonstrating the cardio-protective role of HDL (in 




Figure 3. CVD risk predicted versus HDL-C and LDL-C levels 
in the PROCAM study. Data were from 7152 males between 
35–65 years of age. The total of coronary events in 10 years 
was of 406[13].  
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of low HDL-C levels for predicting elevated CVD risk 
at the individual patient level[15–18]. For example, low 
levels of HDL-C (e.g., < 0.90 mmol/L or 35 mg/dL) 
are associated with a particularly elevated risk of death 
due to CVD, corresponding to 4.1-fold increased risk 
in men and 3.1-fold in women[17]. 
These data highlight that low HDL-C and low HDL 
particle number are important targets of therapies 
aiming to reduce the residual risk of CVD.  
2. Strategies for Managing Patients with Low 
HDL-C 
Therapeutic treatment options for managing patients 
with low HDL-C levels and low HDL particle number 
are currently limited, although several compounds 
targeting HDL are currently in clinical development. 
Increasing the number of functional HDL particles 
represents an important therapeutic approach for the 
next major advance in treating atherosclerosis. There 
are two main strategies for increasing functional HDL. 
The first approach is to use HDL mimetic therapy 
based on administration of small, empty and function-
al pre-β HDL particles to increase the overall transport 
capacity for cholesterol, and thereby increase its eli-
mination. The second strategy is focused on the use of 
small molecules to increase the number of HDL par-
ticles. Recently, activation of the P2Y13 receptor 
(P2Y13R) has been shown to directly increase the 
uptake of HDL-C by the liver facilitating elimination 
of lipids. Consequently, P2Y13R agonists have poten-
tial for improving RLT.  
2.1 Therapies that Increase the Number of Func-
tional HDL 
2.1.1 HDL Mimetics 
During the last two decades, several attempts have 
been made to develop an HDL mimetic capable of 
inducing regression of atherosclerotic plaques. These 
treatments were mainly designed to optimize choles-
terol mobilization and for treatment of patients post 
ACS. HDL mimetic therapy in post-ACS patients sh-
ould increase cholesterol transport via the RLT path-
way by providing an additional capacity to eliminate 
cholesterol by infusing pre-β HDL particles and thus 
to reduce atherosclerotic plaques throughout the body 
vessels. The elimination of cholesterol accumulated in 
the vessel wall, especially during the acute phase of 
increased vulnerability to cardiovascular recurrence 
post-ACS, has the potential to result in a rapid and 
significant reduction in atherosclerotic plaques, and 
stabilization of the lesions leading to less recurrent 
events. 
The importance of using/creating functional HDL 
particles was highlighted recently by the report by 
Voight et al.[19] showing that the sole increase in the 
HDL-C in humans, will not necessarily improve the 
protection against myocardial infarction[19]. Standard 
assays to evaluate LDL-C and HDL-C quantify the ch-
olesterol content within the respective lipoprotein frac-
tions which only indicates the distribution of choles-
terol in different lipoprotein particles at a given time. 
However, these measures do not indicate if the lipo-
protein particles are functional and actively transfer-
ring cholesterol to the liver for elimination. Both LDL 
particles (LDL-p) and HDL particles (HDL-p) vary in 
their content of cholesterol, and thus determining the 
number of lipoprotein particles may be more predic-
tive than estimating the cholesterol concentration in 
assessing the cardiovascular risk. This hypothesis was 
supported by the data from the Framingham offspring 
study on LDL-C[20] and more recently for HDL-C in 
the MESA (Multi-Ethnic Study of Atherosclerosis) 
trial[14]. This report demonstrated a more consistent 
inverse association between cardiovascular endpoints 
and HDL-p compared with HDL-C. These findings 
suggest that a direct quantification of the concentra-
tion of HDL-p may be more useful to define the car-
diovascular risk and to evaluate novel HDL-directed 
therapies which could modulate such lipoprotein par-
ticles metabolism[21]. 
The first randomized trial of HDL infusion in hu-
mans examined the effects of intravenous administra-
tion of recombinant apolipoprotein (apo) A-Imilano (a 
naturally occurring mutated form of human apoA-I 
with Arg-173 to Cys substitution) in a complex with 
synthetic phosphatidylcholine (ETC-216). This apoA- 
Imilano complex produced a significant reduction over 
baseline in coronary atherosclerosis as measured by 
intravascular ultrasonography (IVUS)[22]. Another study, 
using purified apoA-I from human plasma combined 
with soybean phosphatidylcholine (CSL-111), showed 
significant improvements in the plaque characterisa-
tion index and coronary score on quantitative coronary 
angiography in humans[23]. This observation, was con-
firmed in a trial in which atherectomy to excise plaque 
was performed on the superficial femoral artery of 
patients (n = 10) with claudication. Significant im-
provement of the lipid content, the macrophage size 
and inflammation markers of the plaques were ob-
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served after a single infusion of CSL-111 80 mg/kg[24]. 
Recently, three clinical trials have examined the ef-
fects of CER-001, a negatively charged lipoprotein 
complex consisting of phospholipid and recombinant 
human apoA-I that mimics the structure and function 
of natural HDL. Infusion of CER-001 was observed to 
improve carotid wall thickness of patients with famili-
al hypercholesterolaemia[25] and those with hypo-alp-
halipoproteinaemia[26]. CER-001 also improved coro-
nary plaque burden measured by IVUS at the lowest 
tested dose (3 mg/kg) versus baseline and versus pla-
cebo in post-ACS patients[27,28]. The results of studies 
with CER-001 are reviewed elsewhere[29]. 
2.1.2 Small-molecule HDL-increasing Therapies 
There have been several attempts to increase the HDL- 
C levels using pharmacological intervention. HDL-C 
levels have been reported to be increased upon chronic 
administration of fibrates in animals and also in hu-
mans[30]. Niacin is the only drug that has been availa-
ble for patients to raise HDL-C[31]. However, recent 
data from large clinical trials with niacin did not show 
any significant improvement in the cardiovascular risk 
over statins, commonly used for lipid management[32]. 
(1) RVX-208 
RVX-208 (Resverlogix Corp) induces the synthesis of 
apoA-I by selectively binding to the bromodomains of 
bromo and extraterminal (BET) transcriptional regu-
lators[33]. In ASSERT, a Phase II study involving 299 
patients, RVX-208 administered over 12 weeks failed 
to meet its primary endpoint (i.e., the percent change 
in ApoA-I from baseline for each treatment arm com-
pared to placebo) and did not increase HDL by the 
magnitude expected. The highest dose of RVX-208 
(300 mg/day) increased apoA-I by only approximately 
4.5% and HDL by approximately 7%. In addition, a 
number of RVX-208-treated patients experienced ele-
vations in transaminases, a marker of liver injury, to at 
least three times above the upper limit of normal, 
compared with no rise in the placebo group[34]. 
Recent findings of the Phase II(b) trial, ASSURE, 
indicate that RVX-208 does not appear to induce re-
gression of atherosclerotic plaque. This study ex-
amined the effect of treatment on plaque regression in 
324 high-risk CVD patients over 6 months. The study 
did not meet its primary endpoint, namely a 0.6% 
change in percent atherosclerotic volume (PAV) as 
determined by IVUS[35]. In a post-hoc analysis of this 
study, regression of atherosclerotic plaque as meas-
ured by the change from baseline in PAV (−0.75%) 
and total atherosclerotic volume (TAV; −6.3 mm3) was 
observed in patients with high levels of C-reactive 
protein (CRP) treated with RVX-208. The comparison 
with placebo was not reported. When data on major 
adverse cardiovascular events (MACE) from both 
ASSURE and another RVX-208 Phase II study, 
SUSTAIN[36], were combined (n = 499), the rate of 
MACE in patients treated with RVX-208 (n = 331) 
was lower compared with patients receiving placebo 
(n = 168; 6.74% vs 15.09%; p = 0.02)[37]. Furthermore, 
in patients with CRP greater than 2.0 mg/dL (n = 283), 
The benefit of RVX-208 treatment appeared more 
pronounced and the rate of MACE was 6.42% in 
RVX-208-treated (n = 179) compared with 20.53% in 
the placebo group (n = 104; p = 0.007).  
A Phase III study of RVX-208 (BETonMACE) has 
recently been initiated. This multi-center, double-blind, 
randomized, parallel-group trial will compare treat-
ment with RVX-208 100 mg twice daily for up to 104 
weeks compared with placebo in high-risk type 2 di-
abetes mellitus patients with coronary artery disease 
(CAD). The primary endpoint is the time to first oc-
currence of MACE. 
(2) CETP Inhibitors 
Agents in the “-cetrapib” class increase HDL-C by 
inhibition of cholesteryl ester transfer protein (CETP), 
a protein that plays a key role in modulating the ex-
change of cholesteryl esters (CE) and triglycerides. 
There is intense debate in the scientific community 
about whether inhibition of CETP, which increases 
cholesterol content and therefore the size of the HDL 
particle by enhanced CE transfer via LDL particles, is 
actually effective at improving the RLT pathway and 
ultimately resulting in plaque regression. Some ex-
perts contend that the HDL particles becomes so 
overloaded with cholesterol by this mechanism that 
the “constipated” particles become non-functional and 
are no longer able to unload cholesterol in the liver. 
Several agents in this class have been examined in 
clinical trials, three agents failed to show reduction of 
CV outcome and only anacetrapib and Dezima 001 
(also initially named TA-8995) remain in late stage 
clinical development. 
Torcetrapib (Pfizer) was developed for use in com-
bination with atorvastatin. Torcetrapib decreased LDL- 
C levels by approximately 15% and increased HDL-C 
levels by 50–100% depending on the dose. A limiting 
adverse effect of torcetrapib was a significant rise in 
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blood pressure. The compound was tested in a large 
Phase III study, ILLUMINATE, to examine its impact 
on atherosclerotic events[38]. Despite increasing HDL- 
C and reducing LDL-C, the combination of atorvastatin 
and torcetrapib increased rather than decreased MACE 
compared with atorvastatin alone. The trial was ter-
minated prematurely due to increased cardiovascular 
events and mortality in the torcetrapib arm. Other 
clinical studies and follow-up analyses clarified that 
the observed adverse cardiovascular events were 
compound specific and that pursuing further clinical 
development with other compounds was possible.  
Dalcetrapib was developed by Roche after being 
licensed from Japan Tobacco. It produced relatively 
modest effects on the lipid profile in Phase II studies. 
dal-PLAQUE, a Phase II imaging study of dalcetrapib 
in patients with, or at high risk of, coronary heart dis-
ease (CHD) showed only a modest decrease in plaque 
volume after 24 months[39], smaller than that achieved 
with high-dose statin treatment over the same time 
period. Development of Dalcetrapib was halted in 
2012 following an interim analysis that concluded the 
Phase III trial, dal-OUTCOMES as dalcetrapib failed 
to show a reduction in the rate of cardiovascular events 
compared with placebo[40].  
Anacetrapib (Merck) is currently in Phase III clini-
cal development. The results of a Phase II study with 
anacetrapib, DEFINE, were published in 2010[41]. At 
24 weeks, anacetrapib decreased LDL-C by 40% and 
increased HDL-C by 138% in patients with, or at risk 
of, CHD, who were already treated with a statin. 
There was no significant difference in blood pressure 
between the patients treated with anacetrapib versus 
placebo. REVEAL, a large-scale clinical study is cur-
rently ongoing and Merck plans to submit its market-
ing authorization request in 2015 or 2016. The impor-
tant finding that anacetrapib accumulates in adipose 
tissues due to the strong intrinsic lipophilicity of the 
component was reported recently. Although no specif-
ic safety findings have been noted so far, this observa-
tion may have substantial implications on its future 
clinical development.  
Evacetrapib (Lilly) was in Phase III development 
until very recently. Data from a 400-patient Phase II 
trial designed to assess the impact on efficacy (LDL-C 
and HDL-C) and safety, of adding different doses of 
the compound to standard statin doses were reported 
in 2011[42]. In this study, evacetrapib was tested for 12 
weeks, alone or in combination with simvastatin 40 
mg/day, atorvastatin 20 mg/day or rosuvastatin 10 
mg/day in patients with elevated LDL-C or a low level  
of HDL-C. Evacetrapib alone produced a dose-dep-
endent increase in HDL-C from 53.6% to 128.8% and 
a decrease in LDL-C of between 13.6% and 35.9%. 
When given in combination with a statin, Evacetrapib 
produced increases in HDL-C of 78.5% to 88.5% and 
decreases in LDL-C of between 11.2% and 13.9% 
compared with statin monotherapy. The Phase III trial, 
ACCELERATE, was a multi-center, randomized, dou-
ble-blind, placebo-controlled trial to evaluate the effi-
cacy and safety of evacetrapib in participants (n = 
12,095) with high-risk atherosclerotic CVD. The pri-
mary outcome measure was time to first occurrence of 
cardiovascular death, MI, stroke, coronary revascula-
rization, or hospitalization for unstable angina. The 
study was terminated recently on the advice of the 
independent data monitoring committee because of a 
lack of efficacy in the interim analysis. The failure of 
this trial raises the question of whether lack of effica-
cy for reducing CVD events is a class effect of these 
compounds. This study raised also the question about 
the validity of measuring cellular cholesterol efflux 
capacity as a predictive marker of CVD risk as both 
dalcetrapib and evacetrapib increase cellular choles-
terol efflux capacity but failed to reduce CVD risk. 
Such results also raised the concern that the LDL-C 
lowering (on top of statin therapy — see above) is not 
always linked to CVD risk. 
TA-8995 is a less lipophilic compound that was li-
censed from Mitsubishi Tanabe Pharma by Dezima, a 
Dutch biotechnology company. Positive effects of this 
compound on HDL-C were recently reported from a 
small Phase II(b) study as 364 patients were enrolled. 
At week 12, LDL cholesterol levels were reduced in a 
dose-dependent manner between 27.4% to 45.3% at 
the 10 mg dose. LDL cholesterol levels were reduced 
by 68.2% in patients given 10 mg TA-8995 plus ator-
vastatin, and by 63.3% in patients given rosuvastatin 
plus 10 mg TA-8995. A daily dose of TA-8995 in-
creased HDL cholesterol levels between 75.8%, up to 
179.0%. In patients receiving 10 mg TA-8995 and 20 
mg atorvastatin HDL cholesterol levels increased by 
152.1% and in patients receiving 10 mg TA-8995 and 
10 mg rosuvastatin by 157.5%. No serious adverse 
events or signs of liver or muscle toxic effects were 
recorded[43].  
2.2 Therapies that Directly Increase Removal 
of Lipids by the Liver 
P2Y13R Agonists 
The discovery of F1-ATPase and the P2Y13R in the 
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liver, which regulates recognition of HDL-C, added to 
our understanding of HDL metabolism and identified 
new therapeutic targets for treating atherosclerosis. 
Indeed, a nucleotidase activity of ectopic F1-ATPase 
subunit presents at the cell surface of hepatocytes, 
allows the hydrolysis of ATP to ADP which in turn 
stimulates the P2Y13R resulting in the uptake of the 
HDL by the cells[44,45]. The P2Y13R receptor belongs 
to the well-known family of the P2Y receptors, which 
includes P2Y12R, target of successful platelet an-
ti-aggregation drugs. 
In vitro and in vivo tests have demonstrated the in-
creased HDL-C uptake by liver cells (hepatocytes) 
upon stimulation of the activity of HDL receptors in 
the liver and hence increasing the RLT by promoting 
HDL recognition by the liver. This causes a decrease 
in the circulating HDL-C levels (mature HDL particles 
loaded with cholesterol) and leads to increased elimi-
nation of cholesterol in the feces, which should have a 
beneficial effect on atherosclerosis by reducing further 
cholesterol accumulation. Instead of “pushing” the 
cholesterol to the liver by increasing the number of 
HDL particles transporting cholesterol, as with HDL  
mimetics, increasing P2Y13R activity would result in 
better "traction" of HDL-C being “pulled out” of the 
body by the increased activity of the liver receptors 
(Figure 4). Another potential benefit of this increase in 
P2Y13R activity is an improvement in overall liver 
metabolism because the increased cholesterol flow to 
the liver would be accompanied by an increase in 
gallbladder secretion of cholesterol and lipids. This, in 
turn, translates into a decrease in triglycerides and 
cholesterol levels in the serum and in the liver[46] and 
would result in a “healthier” liver.  
Preclinical studies of the P2Y13R agonist, CER- 
209, have shown that it increases elimination of ma-
ture HDL particles loaded with cholesterol, and this 
effect is accompanied by a compensation in the syn-
thesis of HDL, resulting in an increase in the number 
of small circulating HDL particles. In an atherosclero-
sis model in rabbits, 4 weeks of treatment with CER- 
209 induced a 30% regression of atherosclerotic pla-
ques in the aorta as assessed by measuring the choles-
terol content of the artery, and this was confirmed by 




Figure 4. Hepatic P2Y13R receptor pathway. Lipid-free-apoA-I would bind to the ectopic F1-ATPase complex presents at the cell 
surface and induce local and transient ADP production which by stimulating the P2Y13R will in turn stimulate the HDL endocytosis. 
Consequently, lipids elimination will be increased in the bile. Some agonist of the P2Y13R were already described such as ADP, the 
ATP modified compound Cangrelor® (AR-C69931MX) or CER-209 an new class of P2Y13R agonists. 
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3. Conclusion 
A residual risk of CVD remains in patients with LDL- 
C levels below recommended targets. Low HDL-C 
levels are associated with an increased risk of CVD. 
Therefore, targeting the removal of cholesterol from 
the body by increasing the number, or functionality, of 
HDL particles is an important therapeutic goal. 
HDL mimetic therapy is based on infusion of small 
empty and functional pre-β HDL particles to increase 
the overall transport capacity for cholesterol, thereby 
increasing cholesterol elimination. HDL mimetic 
therapy was mainly designed as acute post-ACS ther-
apy. Studies have shown improvement in atheroscle-
rotic plaque burden assessed by vascular imaging with 
infusion of HDL mimetics. 
Small molecule HDL therapy promotes RLT by 
raising the number of HDL particles. It has potential 
as post-ACS therapy and also as a long-term treatment 
for the prevention of CVD. Most of the Phase III stu-
dies of small molecule HDL therapies, either CETP 
inhibitors or RXV-208, have been designed to ex-
amine the long-term effects of treatment. This is a ta-
cit indication that these classes will more likely dem-
onstrate benefit only over long-term chronic use; i.e. 
the primary effect is a gradual slowing of the progres-
sive accumulation of cholesterol that will become ma-
nifest only over a substantial period of time. The lack 
of efficacy for reducing CVD event rate in Phase III 
studies of CETP inhibitors performed to date has 
called in to question the effectiveness of this mechan-
ism of increasing HDL-C and decreasing LDL-C. 
In contrast with compounds that increase the num-
ber of HDL particles, P2Y13R agonists improve RLT 
by increasing the uptake of cholesterol by hepatocytes, 
thereby promoting elimination of accumulated cho-
lesterol and also facilitating the elimination of lipids 
in the bile. The preclinical data on P2Y13R agonists 
support their potential as pharmacological therapy for 
atherosclerotic disease and liver disease such as 
NAFLD (Non-Alcoholic Fatty Liver Disease) and 
NASH (Non-Alcoholic Steato-Hepatitis). 
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